Evidence map›Paper›PMID 30185803›Full record

ArticleScientific reports2018

Characterization of a lung epithelium specific E-cadherin knock-out model: Implications for obstructive lung pathology.

S Post, I H Heijink, L Hesse, H K Koo, F Shaheen, M Fouadi, V N S Kuchibhotla, B N Lambrecht, A J M Van Oosterhout, T L Hackett and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05365841 (Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps), which is not on this map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05365841 unknown statusnot on this mapstarted 2022, after this paper: background citation

Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). Can Shedding of Epithelial Barrier Proteins be Used as Biomarker in Severe Asthma With/Out CRSwNP Management?

TypeobservationalSponsorUniversity of CreteRan2022 to 2025Enrolled85ConditionsSevere Eosinophilic Asthma w/wo CRSwNPArmsMepolizumab 100 MG
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Generation of Human 3D Airway Assembloids for Advanced Modeling.International journal of biological sciences · 2025
    Article
  12. Article
  13. Article
  14. The epithelial era of asthma research: knowledge gaps and future direction for patient care.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  15. Fungal Aeroallergens-The Impact of Climate Change.Journal of fungi (Basel, Switzerland) · 2023
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

S PostUniversity of Groningen, University Medical Center Groningen, Department of Pathology & Medical Biology, laboratory of Experimental Pulmonology and Inflammation Research (EXPIRE), Groningen, The Netherlands.
I H HeijinkUniversity of Groningen, University Medical Center Groningen, Department of Pathology & Medical Biology, laboratory of Experimental Pulmonology and Inflammation Research (EXPIRE), Groningen, The Netherlands. h.i.heijink@umcg.nl.
L HesseUniversity of Groningen, University Medical Center Groningen, Department of Pathology & Medical Biology, laboratory of Experimental Pulmonology and Inflammation Research (EXPIRE), Groningen, The Netherlands.
H K KooUniversity of British Columbia, Centre for Heart and Lung Innovation, Department of Anesthesiology, Pharmacology and Therapeutics, St. Paul's Hospital, Vancouver, British Columbia, Canada.
F ShaheenUniversity of British Columbia, Centre for Heart and Lung Innovation, Department of Anesthesiology, Pharmacology and Therapeutics, St. Paul's Hospital, Vancouver, British Columbia, Canada.
M FouadiUniversity of British Columbia, Centre for Heart and Lung Innovation, Department of Anesthesiology, Pharmacology and Therapeutics, St. Paul's Hospital, Vancouver, British Columbia, Canada.
V N S KuchibhotlaUniversity of Groningen, University Medical Center Groningen, Department of Pathology & Medical Biology, laboratory of Experimental Pulmonology and Inflammation Research (EXPIRE), Groningen, The Netherlands.
B N LambrechtLaboratory of Immunoregulation and Mucosal Immunology, Department for Molecular Biomedical Research, Inflammation Research Centre (IRC), Ghent, Belgium.
A J M Van OosterhoutUniversity of Groningen, University Medical Center Groningen, Department of Pathology & Medical Biology, laboratory of Experimental Pulmonology and Inflammation Research (EXPIRE), Groningen, The Netherlands.
T L HackettUniversity of British Columbia, Centre for Heart and Lung Innovation, Department of Anesthesiology, Pharmacology and Therapeutics, St. Paul's Hospital, Vancouver, British Columbia, Canada.
M C NawijnUniversity of Groningen, University Medical Center Groningen, Department of Pathology & Medical Biology, laboratory of Experimental Pulmonology and Inflammation Research (EXPIRE), Groningen, The Netherlands.
University Medical Center Groningen · NLUniversity of Groningen · NLSt. Paul's Hospital · CAUniversity of British Columbia · CAGhent University Hospital · BE

Funding

Canadian Institutes for Health Research 260046
6 · The paper itself

Abstract

The airway epithelium regulates responses to aeroallergens, acting as a physical and immunological barrier. In asthma, epithelial barrier function and the expression of adherens junction protein E-cadherin is compromised, but it is unknown whether this is cause or consequence of the disease. We hypothesized that airway epithelial loss of E-cadherin is a critical step in the development of manifestations of asthma. We generated a transgenic mouse model with conditional loss of E-cadherin in lung epithelial cells at birth and onwards. We observed normal lung development at the time of birth in mice lacking E-cadherin in the lung epithelium. However, E-cadherin deficiency led to progressive epithelial damage in mice growing into adulthood, as evidenced by airway epithelial denudation, decreased zonula occludens (ZO)-1 expression, loss of ciliated cells, and enlarged alveolar spaces. In addition, spontaneous goblet cell metaplasia with mucus production was observed. These epithelial changes were accompanied by elevated levels of the epithelial-derived chemokine CCL17, infiltration of eosinophils and dendritic cells, and mucus production. In conclusion, loss of E-cadherin induces features in the lung reminiscent of those observed in asthma, indicating that the disruption of E-cadherin-mediated cell-cell contacts may play a key role in the development of asthma manifestations.

Indexed as

Adherens JunctionsAnimalsAsthmaCadherinsChemokine CCL17Dendritic CellsDisease Models, AnimalEosinophilsEpithelial CellsEpitheliumGoblet CellsLungMetaplasiaMiceMice, Inbred C57BLMice, TransgenicCadherinsCcl17 protein, mouseChemokine CCL17Zonula Occludens-1 Protein

Identifiers

PMID30185803
PMCPMC6125431
OpenAlexW2889297418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.